Roquefort Therapeutics plc

LSE ROQ.L

Roquefort Therapeutics plc Price to Earnings Ratio (P/E) on January 14, 2025: -2.69

Roquefort Therapeutics plc Price to Earnings Ratio (P/E) is -2.69 on January 14, 2025, a 55.45% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Roquefort Therapeutics plc 52-week high Price to Earnings Ratio (P/E) is -2.42 on December 20, 2024, which is 10.12% above the current Price to Earnings Ratio (P/E).
  • Roquefort Therapeutics plc 52-week low Price to Earnings Ratio (P/E) is -7.95 on February 27, 2024, which is -195.66% below the current Price to Earnings Ratio (P/E).
  • Roquefort Therapeutics plc average Price to Earnings Ratio (P/E) for the last 52 weeks is -4.20.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
LSE: ROQ.L

Roquefort Therapeutics plc

CEO Mr. Trevor Ajanthan Reginald
IPO Date March 22, 2021
Location United Kingdom
Headquarters Eccleston Yards
Employees 10
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

StockViz Staff

January 15, 2025

Any question? Send us an email